Cargando…

GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism

OBJECTIVES: Tacrolimus is characterized by high pharmacokinetic variability in combination with a narrow therapeutic range. However, influence of donor CYP3A5 genotype and graft-to-recipient body weight ratio (GRWR) on tacrolimus' pharmacokinetics after pediatric living donor liver transplantat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Ping, Hou, Yuchen, Qiu, Bijun, Feng, Mingxuan, Yang, Taihua, Luo, Yi, Xia, Lei, Chen, Xiaosong, Zhang, Jianjun, Xue, Feng, Xia, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637468/ https://www.ncbi.nlm.nih.gov/pubmed/36349313 http://dx.doi.org/10.1155/2022/7647754

Ejemplares similares

Modified Dual Hepatic Vein Anastomosis in Pediatric Living-Donor Liver Transplantation Using Left Lateral Segment Grafts With Two Wide Orifices
por: Hou, Yuchen, et al.
Publicado: (2021)

Pediatric living-donor liver transplantation using right posterior segment grafts
por: Qu, Xiaoye, et al.
Publicado: (2021)

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
por: Mendrinou, Effrosyni, et al.
Publicado: (2020)

Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation
por: Chen, Yi-kuan, et al.
Publicado: (2014)

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
por: Wu, Zhengshan, et al.
Publicado: (2013)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

Pure Laparoscopic Living Donor Hepatectomy With/Without Fluorescence-Assisted Technology and Conventional Open Procedure: A Retrospective Study in Mainland China
por: He, Kang, et al.
Publicado: (2021)

CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation
por: Ji, Eunhee, et al.
Publicado: (2018)

The impact of preformed donor‐specific antibodies in living donor liver transplantation according to graft volume
por: Goto, Ryoichi, et al.
Publicado: (2022)

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
por: Kim, Hyeyoung, et al.
Publicado: (2014)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Mental health in children with living donor liver transplantation: a propensity score-matched analysis
por: Huang, Mingzhu, et al.
Publicado: (2022)

Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients
por: Raj, T. Yashwanth, et al.
Publicado: (2022)

447 Infectious complication and mortality after Liver Transplantation according to Donor: comparison between Cadaveric and Living Donor Transplantation
por: Lee, Su Jin, et al.
Publicado: (2014)

Outcomes of Living-Donor Kidney Transplantation in Female Recipients with Possible Pregnancy-Related Pre-Sensitization According to Donor Relationship
por: Kim, Jee Yeon, et al.
Publicado: (2020)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation
por: Song, Turun, et al.
Publicado: (2019)

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
por: Sapisochin, Gonzalo, et al.
Publicado: (2022)

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantation
por: Huang, Li, et al.
Publicado: (2021)

Adult Living-Donor Kidney Transplantation, Donor Age, and Donor–Recipient Age
por: Hiramitsu, Takahisa, et al.
Publicado: (2021)

A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
por: Liu, Yuan, et al.
Publicado: (2017)

Analysis of Donor Motivations in Living Donor Liver Transplantation
por: Abdeldayem, Hesham, et al.
Publicado: (2014)

Donor Surgical Morbidity in Pediatric Living-Donor Liver Transplant: A Portuguese Experience
por: dos Santos, José Pedro Fernandes, et al.
Publicado: (2021)

Pyrosequencing to Identify Homogeneous Phenomenon When Using Recipients/Donors with Different CYP3A5*3 Genotypes in Living Donor Liver Transplantation
por: Chiu, King-Wah, et al.
Publicado: (2013)

Outcomes of living donor liver transplantation using elderly donors
por: Han, Jae Hyun, et al.
Publicado: (2014)

Corrigendum: Analysis of donor motivations in living donor liver transplantation
por: Abdeldayem, Hesham, et al.
Publicado: (2020)

Pulmonary Embolism in a Donor of Living Donor Liver Transplantation
por: Onda, Shinji, et al.
Publicado: (2019)

Uterus Transplantation: From a Deceased Donor or Living Donor?
por: Kisu, Iori, et al.
Publicado: (2022)

Cancer Incidence in Living Liver Donors After Donor Hepatectomy
por: Kim, Jongman, et al.
Publicado: (2023)

Donor Smoking Negatively Affects Donor and Recipient Renal Function following Living Donor Nephrectomy
por: Heldt, Jonathan, et al.
Publicado: (2011)

Is Bigger Better? Living Donor Kidney Volume as Measured by the Donor CT Angiogram in Predicting Donor and Recipient eGFR after Living Donor Kidney Transplantation
por: Ebad, Chaudhry Adeel, et al.
Publicado: (2021)

Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry
por: Kasiske, Bertram L., et al.
Publicado: (2021)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Outcome of living kidney donors according to national data of turkish organ and tissue information system
por: Kapuağası, A, et al.
Publicado: (2015)

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
por: Saidi, R. F., et al.
Publicado: (2013)

Preoperative CT evaluation of potential donors in living donor liver transplantation
por: Vohra, Sandeep, et al.
Publicado: (2014)

Outcome of donor biliary complications following living donor liver transplantation
por: Woo, Hyun Young, et al.
Publicado: (2018)

Recipient Outcomes with Younger Donors Undergoing Living Donor Liver Transplantation
por: Dar, Faisal S, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_51b00m4jlflk8e7l0ltnp3tv24